Outcome measures in inflammatory rheumatic diseases

被引:0
作者
Jaap Fransen
Piet LCM van Riel
机构
[1] Radboud University Nijmegen Medical Centre,Department of Rheumatology
来源
Arthritis Research & Therapy | / 11卷
关键词
Rheumatoid Arthritis; Rheumatic Disease; Psoriatic Arthritis; Disease Activity Index; Bath Ankylose Spondylitis Disease Activity Index;
D O I
暂无
中图分类号
学科分类号
摘要
Inflammatory rheumatic diseases are generally multifaceted disorders and, therefore, measurement of multiple outcomes is relevant to most of these diseases. Developments in outcome measures in the rheumatic diseases are promoted by the development of successful treatments. Outcome measurement will increasingly deal with measurement of low levels of disease activity and avoidance of disease consequences. It is an advantage for patient management and knowledge transfer if the same outcomes are used in practice and in trials. Continuous measures of change are generally the most powerful and, therefore, are preferred as primary outcomes in trials. For daily clinical practice, outcome measures should reflect the patients' state and have to be easily derivable. The objective of this review is to describe recent developments in outcome measures for inflammatory rheumatic diseases for trials and clinical practice, with an emphasis on rheumatoid arthritis.
引用
收藏
相关论文
共 318 条
[41]  
Cobb S(2008)Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations Arthritis Rheum 59 1371-1317
[42]  
Anderson F(2009)Contemporary treatment principles for early rheumatoid arthritis: a consensus statement Rheumatology 48 765-772
[43]  
Bauer W(2008)American College of Rheumatology 2008 Recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis Arthritis Rheum 59 762-784
[44]  
Sokka T(2007)EULAR recommendations for the management of early arthritis: Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Dis 66 34-45
[45]  
Pincus T(2004)Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial Lancet 364 263-269
[46]  
Boers M(2007)Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial) Ann Rheum Dis 66 1443-1449
[47]  
Dijkmans B(2005)Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial Ann Rheum Dis 64 1294-1298
[48]  
Gabriel S(undefined)undefined undefined undefined undefined-undefined
[49]  
Maradit-Kremers H(undefined)undefined undefined undefined undefined-undefined
[50]  
O'Dell J(undefined)undefined undefined undefined undefined-undefined